Temporal Concept – Page 5

Takeda Makes Pipeline Cuts and Faces Softer Q2 Sales Due to Generic Competition

2 months ago talkbio0Tagged Drug Development, Generic competition, impairment charges, Late stage, Operating, pipeline, Q2 sales, restructuring, Takeda, Vyvanse

Takeda; pipeline cuts; generic competition; Q2 sales; Vyvanse; restructuring; operating profit; impairment charges; drug development; late-stage pipeline

No Recent News on BridgeBio’s Thyroid Disorder Phase 3 Win

2 months ago talkbio0Tagged BridgeBio, Infrequent, Phase 3, Thyroid Diseases

BridgeBio; Phase 3; Rare Diseases; Thyroid Disorder

Expert Insights to Navigate Your CGT Challenges: Recent Updates and Strategic Guidance for 2025

2 months ago talkbio0Tagged calcium glucarate, Capital, Challenge, Changing, Cognitive function: planning, gains, Investments, Long-term, minimization, Private Equity, rates, Taxes

capital gains tax; CGT challenges; 2025 tax rates; long-term capital gains; tax planning; tax minimization strategies; Net Investment Income Tax; private equity tax changes

Intellia Pauses Two CRISPR Trials After Severe Liver Toxicity Hospitalizes Patient

2 months ago talkbio0Tagged Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, Hospitalization, Intellia, Liver, Pauses, Phase 3 Clinical Trials, Safety, Senile cardiac amyloidosis, Toxicity aspects

Intellia Therapeutics; CRISPR; transthyretin amyloidosis; Phase III trials; gene editing; liver toxicity; patient hospitalization; safety pause

BridgeBio Shifts Filing Plans After Phase 3 Success in Rare Disease Drug BBP-418

2 months ago talkbio0Tagged Acoramidis, Approved, BBP-418, Biological Markers, BridgeBio, commercial, disease drug, File (record), Infrequent, Limb-girdle muscular dystrophy type 2A, NDA, New Drug Application, Phase 3 success, Ribitol, United States Food and Drug Administration

BridgeBio; BBP-418; Phase 3 success; limb-girdle muscular dystrophy type 2I/R9; FDA filing; rare disease drug; NDA (New Drug Application); ribitol; full approval; biomarker; acoramidis; commercial strategy

From JP Morgan to the Next Wave: What’s Driving Biotech in 2026

2 months ago talkbio0Tagged 2026, Artificial Intelligence, Drug Discovery, Hematology (discipline), Investments, J.P. Morgan Healthcare Conference, M&A activity, Neoplasms, Neuropsychology, regulatory science, trends qualifier

J.P. Morgan Healthcare Conference; biotech trends 2026; M&A activity; oncology; neuropsychology; hematology; artificial intelligence; drug discovery; investment; regulatory science

Inhibrx to Seek FDA Approval in 2026 After Strong Phase 2 Data for Bone Cancer Drug Ozekibart

2 months ago talkbio0Tagged Anti-DR5 Agonistic Monoclonal Antibody INBRX-109, Biological Factors, Chondrosarcoma, Infrequent, Inhibrx, Liver, Malignant Bone Neoplasm, Malignant Neoplasms, ozekibart, Progression-Free Survival, Receptors, Tumor Necrosis Factor, Member 10b, Submission, Toxicity aspects, United States Food and Drug Administration

Inhibrx; FDA submission; ozekibart; INBRX-109; chondrosarcoma; bone cancer; phase 2 clinical trial; progression-free survival; death receptor 5; biologics license application; rare cancer; liver toxicity

Eye Disease Biotech Kala Bio Collapses After Failed Clinical Trial, Lender Takes Control

2 months ago talkbio0Tagged Clinical trial failure, Corneal epithelial defect, Experimental drug, foreclosure proceedings, Kala Bio, KPI-012, lender takeover, Oxford Finance, PCED, Persistent, Shock, Workforce reduction

Kala Bio; biotech collapse; failed drug trial; KPI-012; persistent corneal epithelial defect; PCED; lender takeover; Oxford Finance; foreclosure proceedings; workforce reduction; clinical trial failure

Sanofi’s efdoralprin alfa (INBRX-101) achieves all endpoints in Phase 2 alpha-1 antitrypsin deficiency (AATD) trial

2 months ago talkbio0Tagged Acquisition, alpha 1-Antitrypsin Deficiency, efdoralprin alfa, INBRX-101, Inhibrx, Phase 2, plasma-derived therapy, Rare Diseases, sanofi, Zemaira

Sanofi; efdoralprin alfa; INBRX-101; AATD; alpha-1 antitrypsin deficiency; Phase 2; Inhibrx; acquisition; rare disease; plasma-derived therapy; Zemaira

Connecticut Biotech Veradermics Secures $150M for Phase 3 Trials of Oral Rogaine

2 months ago talkbio0Tagged Biotechnology, Clinical Development, Clinical Trials, Connecticut biotech, Fund Raising, hair loss treatment, Oral cavity, Phase 3, Rogaine, Veradermics

Veradermics; Connecticut biotech; oral Rogaine; Phase 3 clinical trials; fundraising; hair loss treatment; biotechnology; clinical development